Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 50-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of100 Unit of Abobotulinum Toxin Type A (Dysport®) Versus 33.33 Unit of Neubotulinum Toxin Type A (Neuronox®) Injection for Hemifacial Spasm in Thai Patients

NCT04589364 is registered in ClinicalTrials.gov with Department of Medical Services Ministry of Public Health of Thailand as lead sponsor.

NCT NCT04589364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04589364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 50-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of100 Unit of Abobotulinum Toxin Type A (Dysport®) Versus 33.33 Unit of Neubotulinum Toxin Type A (Neuronox®) Injection for Hemifacial Spasm in Thai Patients
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2024
Completion date
August 1, 2026
Enrollment
107 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hemifacial spasm